NextCell Pharma AB (NXTCL) - Total Assets
Based on the latest financial reports, NextCell Pharma AB (NXTCL) holds total assets worth Skr76.73 Million SEK (≈ $8.26 Million USD) as of August 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore NextCell Pharma AB (NXTCL) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
NextCell Pharma AB - Total Assets Trend (2015–2025)
This chart illustrates how NextCell Pharma AB's total assets have evolved over time, based on quarterly financial data. See NXTCL total equity for net asset value and shareholders' equity analysis.
NextCell Pharma AB - Asset Composition Analysis
Current Asset Composition (August 2025)
NextCell Pharma AB's total assets of Skr76.73 Million consist of 70.9% current assets and 29.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 50.5% |
| Accounts Receivable | Skr15.13 Million | 19.7% |
| Inventory | Skr545.24K | 0.7% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how NextCell Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NXTCL company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NextCell Pharma AB's current assets represent 70.9% of total assets in 2025, a decrease from 74.3% in 2015.
- Cash Position: Cash and equivalents constituted 50.5% of total assets in 2025, down from 70.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 19.7% of total assets.
NextCell Pharma AB Competitors by Total Assets
Key competitors of NextCell Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
NextCell Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.02 | 6.14 | 9.81 |
| Quick Ratio | 9.92 | 6.09 | 8.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr48.97 Million | Skr50.75 Million | Skr18.64 Million |
NextCell Pharma AB - Advanced Valuation Insights
This section examines the relationship between NextCell Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.25 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -5.6% |
| Total Assets | Skr76.73 Million |
| Market Capitalization | $12.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values NextCell Pharma AB's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NextCell Pharma AB's assets decreased by 5.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NextCell Pharma AB (2015–2025)
The table below shows the annual total assets of NextCell Pharma AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | Skr76.73 Million ≈ $8.26 Million |
-5.60% |
| 2024-08-31 | Skr81.29 Million ≈ $8.75 Million |
-8.49% |
| 2023-08-31 | Skr88.83 Million ≈ $9.56 Million |
-28.74% |
| 2022-08-31 | Skr124.66 Million ≈ $13.41 Million |
-19.90% |
| 2021-08-31 | Skr155.63 Million ≈ $16.75 Million |
+422.69% |
| 2020-08-31 | Skr29.77 Million ≈ $3.20 Million |
+11.44% |
| 2019-08-31 | Skr26.72 Million ≈ $2.88 Million |
+213.95% |
| 2018-08-31 | Skr8.51 Million ≈ $915.84K |
-60.65% |
| 2017-08-31 | Skr21.63 Million ≈ $2.33 Million |
+128.47% |
| 2016-08-31 | Skr9.47 Million ≈ $1.02 Million |
-23.41% |
| 2015-08-31 | Skr12.36 Million ≈ $1.33 Million |
-- |
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more